Hence, we investigated the capacity of TRIEN in modulating the EMT phenotype in our selection of breast cancer cell lines, by analyzing the changes of the epithelial/mesenchymal markers (E-cadherin, fibronectin, vimentin and αSMA) specifically expressed in each cell line, by Western blot and immunofluorescence analyses (Fig. 2b-h). The gene discussed is ACTA1; the disease is breast carcinoma.